Characteristics | All patients | MSDT | Â | HBMT | Â | ||
---|---|---|---|---|---|---|---|
MRDneg | MRDpos | MRDneg | MRDpos | ||||
Number of patients | 340 | 62 | 20 | Â | 202 | 56 | Â |
Median age (range), years | 32 (3–65) | 39 (4–55) | 41.5 (7–62) | 0.612 | 30 (3–65) | 26 (4–61) | 0.151 |
Weight (range), kg | 62 (15.5–140) | 63 (15.5–91) | 65.25 (28–95) | 0.631 | 62 (17–140) | 58 (19–92) | 0.090 |
Male, n (%) | 208 (61.2%) | 32 (51.6%) | 15 (75.0%) | 0.066 | 127 (62.9%) | 34 (60.7%) | 0.768 |
Diagnosis, n (%) | Â | Â | Â | 0.146 | Â | Â | 0.603 |
 De novo AML | 318 (93.5%) | 61 (98.4%) | 18 (90.0%) |  | 187 (92.6%) | 52 (92.9%) |  |
 Secondary AML | 22 (6.5%) | 1 (1.6%) | 2 (10.0%) |  | 15 (7.4%) | 4 (7.1%) |  |
Disease status, n (%) | Â | Â | Â | Â | Â | Â | 0.165 |
 CR1 | 293 (86.2%) | 56 (90.3%) | 15 (75.0%) | 0.080 | 177 (87.6%) | 45 (80.4%) |  |
 CR > 1 | 47 (13.8%) | 6 (9.7%) | 5 (25.0%) |  | 25 (12.4%) | 11 (19.6%) |  |
FLT3-ITD mutation | Â | Â | Â | 0.390 | Â | Â | 0.610 |
 Yes | 49 (14.4%) | 11 (17.7%) | 2 (10.0%) |  | 27 (13.4%) | 9 (16.1%) |  |
 No | 291 (85.6%) | 51 (82.3%) | 18 (90.0%) |  | 175 (86.6%) | 47 (83.9%) |  |
Cytogenetics | Â | Â | Â | 0.500 | Â | Â | 0.277 |
 Favorable | 43 (12.6%) | 7 (11.3%) | 1 (5.0%) |  | 28 (13.9%) | 7 (12.5%) |  |
 Intermediate | 263 (77.4%) | 50 (80.6%) | 16 (80.0%) |  | 157 (77.7%) | 40 (71.4%) |  |
 Adverse | 34 (10.0%) | 5 (8.1%) | 3 (15.0%) |  | 17 (8.4%) | 9 (16.1%) |  |
Conditioning regimen, n (%) | |||||||
 MA | 340 (100%) | 62 (100%) | 20 (100%) |  | 202 (100%) | 56 (100%) |  |
HLA-A-, B-, and DR-mismatched grafts, n (%) | Â | Â | Â | Â | Â | Â | 0.599 |
 0 | 84 (24.7%) | 62 (100%) | 20 (100%) |  | 2 (1.0%) | 0 |  |
 1 | 7 (2.1%) | 0 | 0 |  | 5 (2.5%) | 2 (3.6%) |  |
 2 | 31 (9.1%) | 0 | 0 |  | 22 (10.9%) | 9 (16.1%) |  |
 3 | 218 (64.1%) | 0 | 0 |  | 173 (85.6%) | 45 (80.4%) |  |
Donor-recipient sex-matched grafts, n (%) | |||||||
 Male–male | 136 (40.0%) | 15 (24.2%) | 6 (30.0%) |  | 94 (46.5%) | 21 (37.5%) |  |
 Male–female | 86 (25.3%) | 14 (22.6%) | 3 (15.0%) |  | 55 (27.2%) | 14 (25.0%) |  |
 Female–male | 75 (22.1%) | 18 (29.0%) | 2 (10.0%) |  | 33 (16.3%) | 15 (26.8%) |  |
 Female–female | 43 (12.6%) | 15 (24.2%) | 9 (45.0%) |  | 20 (9.9%) | 6 (10.7%) |  |
Donor-recipient relationship, n (%) | Â | Â | Â | Â | Â | Â | 0.283 |
 Parent–child | 132 (38.8%) | 0 | 0 |  | 99 (49.0%) | 33 (58.9%) |  |
 Sibling–sibling | 153 (45.0%) | 62 (100%) | 20 (100%) |  | 61 (30.2%) | 10 (17.9%) |  |
 Child–parent | 49 (14.4%) | 0 | 0 |  | 37 (18.3%) | 12 (21.4%) |  |
 Other | 6 (1.8%) | 0 | 0 |  | 5 (2.5%) | 1 (1.8%) |  |
ABO matched grafts, n (%) | Â | Â | Â | Â | Â | Â | 0.344 |
 Matched | 179 (52.6%) | 40 (64.5%) | 14 (70.0%) | 0.660 | 97 (48.0%) | 28 (50.0%) |  |
 Major mismatch | 70 (20.6%) | 10 (16.1%) | 4 (20.0%) |  | 45 (22.3%) | 11 (19.6%) |  |
 Minor mismatch | 72 (21.2%) | 8 (12.9%) | 2 (10.0%) |  | 46 (22.8%) | 16 (28.6%) |  |
 Bi-directional mismatch | 19 (5.6%) | 4 (6.5%) | 0 |  | 14 (6.9%) | 1 (1.8%) |  |
EBMT score, n (%) | Â | Â | Â | 0.125 | Â | Â | 0.546 |
 0 | 2 (0.6%) | 1 (1.6%) | 1 (5.0%) |  | 0 | 0 |  |
 1 | 66 (19.4%) | 21 (33.9%) | 6 (30.0%) |  | 31 (15.3%) | 8 (14.3%) |  |
 2 | 145 (42.6%) | 28 (45.2%) | 6 (30.0%) |  | 90 (44.6%) | 21 (37.5%) |  |
 3 | 91 (26.8%) | 11 (17.7%) | 4 (20.0%) |  | 58 (28.7%) | 18 (32.1%) |  |
 4 | 30 (8.8%) | 1 (1.6%) | 3 (15.0%) |  | 20 (9.9%) | 6 (10.7%) |  |
 5 | 6 (1.8%) | 0 | 0 |  | 3 (1.5%) | 3 (5.4%) |  |
Cell compositions in allografts | |||||||
 Infused nuclear cells, (range) 108/kg | 7.83 (2.27–16.66) | 7.59 (5.18–14.93) (5.18–14.93) | 7.22 (2.27–9.29) | 0.201 | 7.88 (3.93–15.97) | 8.17 (3.44–16.66) | 0.517 |
 Infused CD34+ cells, (range) 106/kg | 2.55 (0.22–10.95) | 2.53 (0.41–6.43) | 2.65 (0.90–5.47) | 0.829 | 2.49 (0.22–10.95) | 2.78 (0.38–7.20) | 0.340 |
DLI after transplant, n (%) | |||||||
 For relapse prophylaxis and intervention | 32 (9.4%) | 5 (8.1%) | 4 (20.0%) | 0.211 | 8 (4.0%) | 14 (25.0%) | <0.001 |
 For relapse treatment | 8 (2.4%) | 2 (3.2%) | 2 (10.0%) | 0.249 | 3 (1.5%) | 2 (3.6%) | 0.297 |